World Journal of Pharmaceutical Sciences
ISSN (Print): 2321-3310; ISSN (Online): 2321-3086
Available online at: https://wjpsonline.com/
Research Article

FORMULATION OF NOVEL NANO TRANSDERMAL USING EFFECTIVE COMBINATION OF ACYCLOVIR AND OMEPRAZOLE FOR ENHANCED ANTI-VIRAL ACTIVITY

[1]Dr. Nansri saha

[1]Associate Professor, Department of Pharmaceutics, SSJ College of Pharmacy, V.N Pally, Hyderabad, Telangana.

Received: 20-12-2024 / Revised Accepted: 24-12-2024 / Published: 03-01-2025

ABSTRACT:

The current review exhibited that Acyclovir and Omeprazole nanogel were effectively evolved by dissolvable dispersion technique .pH was resolved different definition F1-F9 in that F9 have reasonable for gel planning. Drug not entirely set in stone by UV-spectroscopic technique. The arranged nanogel was obscure, with next to no knots, molecule and totals. In this way, every one of the definitions are homogenous. Spreadability measurement concentrate on F9 shown the nanogel is having great Spreadability. Nanogel plans shown consistency territory from 3268-3528 cps. It reasoned that they are steady in nature. In-vitro disintegration study was performed and showed that F9 have great disintegration rate. The molecule size, PDI and zeta potential to figure out the F9 plan. The molecule size, PDI and zeta potential was viewed as in 687.4, 0.842 and -43.7 separately. TEM picture was affirmed the state of round and smooth surface of particles at range 650 nm. Contrasting F9 nanogel definition and acyclovir advertised detailing (MF) by in-vitro discharge study. As per result planned Acyclovir and omeprazole nanogel is more effective than the promoted acyclovir salve. Subsequently from our review the acyclovir and omeprazole nanogel (F9) showed that support drug discharge than the showcased plan, so it is obvious that figuring out into nanogel results increment the counter - viral movement.

Key words: Formulation, Nano Transdermal, Acyclovir, Omeprazole, Anti-Viral Activity

INTRODUCTION

The transdermal drug delivery system (TDDS) is a widely accepted mode of drug delivery, and transdermal patches are devised to treat various diseases [1]. Transdermal delivery leads to over-injectable and oral routes by increasing patient compliance and avoiding the first-pass metabolism, respectively. They can even prevent drug-related gastrointestinal problems and low absorption [2]. The goal of the transdermal drug delivery system is to maximize the skin flux into systemic circulation while reducing the retention and metabolism of the drug in the skin at the same time [3–5]. These therapeutic benefits reflect the higher marketing potential of TDDS [6]. Most of the drug molecules penetrate through the skin through the intercellular micro route and therefore the role of permeation or penetration enhancers in TDDS is vital as they reversibly reduce the barrier resistance of the stratum corneum without damaging viable cells [7].

Omeprazole and other proton pump inhibitors have been found to increase the activity of anti-cancer drugs including the nucleoside analogue 5-fluorouracil [8] Proton pump inhibitors are the most frequently prescribed drugs for the treatment and prophylaxis of gastroesophageal reflux as well as of gastric and duodenal ulcers that are associated with hyper-acidic states. Since they are known to be well-tolerated, they were suggested as repositioning candidates for the use as part of anti-cancer therapies [9]

Acyclovir is activated by the viral thymidine kinase and then di- and tri-phosphorylated by cellular kinases. The active tri-phosphorylated forms of acyclovir and then specifically interferes with the viral DNA polymerase and causes chain termination [10,11]. Ribavirin is a guanosine analogue that has been shown to exert broad-spectrum activity against RNA and DNA viruses including influenza viruses and West Nile virus. The mechanisms by which ribavirin interferes with virus replication are not clear and may be virus-dependent [12,13,14]

Address for Correspondence: Associate Professor, Department of Pharmaceutics, SSJ College of Pharmacy, V.N Pally, Hyderabad, Telangana.; **E-Mail:** nansrisaha@gmail.com.

How to Cite this Article: Dr. Nansri saha. PREPARATION AND EVALUATION OF RIFAMPICIN - ASCORBIC ACID LOADED PLGA NANOPARTICLES. World J Pharm Sci 2025; 13(01): 69-85; https://doi.org/10.54037/WJPS.2022.100905

METHODOLOGY:

PREFORMUALTION STUDIES: Preformulation studies include physical, synthetic and organic portrayal of new medication substances to foster steady, protected and successful dose structure. Preformulation testing envelops all reviews established on a medication compound to create valuable data for resulting definition of a stable and bio-chemically reasonable medication measurements structure.

Physical attributes: By visual assessment the medication was tried for its actual characters like tone, smell and surface.

Melting Point: The computerized dissolving point device was utilized to decide the softening place of medication. A hairlike cylinder was taken and intertwined at one side with the assistance of a Bunsen burner. The medication acyclovir and omeprazole was brought into the narrow cylinder through the unlocked end and afterward positioned in a softening point watcher. Then, at that point, the temperature at which medication begins liquefying was considered as the dissolving point of the drug.

Solubility test: Acyclovir and Omeorazole powder (around 1mg) was stepped through in an examination cylinder and dissolvability in ethanol, water, PH cushion 7.4 and methanol was tried.

Determination of λ max: 10 mg of precisely gauged acyclovir and omeprazole was broken up in 10 ml of 7.4 pH cushion in a 100 ml volumetric cup. It was made up to 100 ml by utilizing refined water to get a centralization of 100 µg/ml (Stock A). From the above stock arrangement A, convergence of 2µg/ml was ready by pippeting 0.2 ml and made up to 10 ml utilizing the medium. The arrangement was checked by utilizing twofold shaft UV noticeable spectrophotometer between the frequency scopes of 200 nm to 400 nm.

Standard Bend: 10 mg of precisely gauged acyclovir and omeprazole was independently broken down in 10 ml of 7.4 pH cushion and refined water in a 100 ml utilizing phosphate cradle pH 7.4 to get a centralization of 100 µg/ml (Stock A). From the above stock arrangement A, focus goes from 2µg/ml to 10 µg/ml was ready by pippeting 0.2 ml to 1 ml. It was made up to 10 ml utilizing medium. The absorbance of every focus was broke down in the UV noticeable twofold bar Spectrophotometer at 252 nm and 305 nm separately. The connection coefficient not set in stone from the diagram. An alignment bend was plotted with focus on the x-pivot and absorbance on the Y-hub.

FT-IR Studies (Medication Polymer Similarity): Drug polymer still up in the air by KBr pellet strategy utilizing Fourier Change Infrared Spectrophotometer. The examples were ready by KBr pellet press technique and it was filtered between 400-4000 cm-1.

FORMULATION OF ACYCLOVIR AND OMEPRAZOLE NANOGEL

Preparation of acyclovir and omeprazole Nanogel:

Acyclovir and omeprazole nanogel arranged by Nano dissolvable dissemination technique Precisely gauged amount of medication is disintegrated in ethanol and propylene glycol with mixing (natural stage). In the second step fluid stage is ready by utilizing Carbopol - 940 broke down in water with constant mixing and intensity for a 20 min in an attractive blending. Also, the medication stage is sonicated under ultrasonic shower Sonicator for 10 min. On following stage drug stage is added drop by drop into watery stage during high velocity homogenization for 30 min at 6000 rpm to from emulsion. The emulsion is changed over into nanodroplet by homogenizer brings about o/w emulsion framed. Then o/w emulsion is homogenized for 1 h at 8000 rpm and triethanolamine is added with blends to from nanogel (utilizing a mix of ultra- sonication and rapid homogenization). Carbopol and tracaganth were utilized as a gel shaping polymer which were taken separately and in mix. The detailing code has been displayed in table.

Table.1: Formulation Table of Nanogel.

Formulation code	F1	F2	F3	F4	F5	F6	F7	F8	F9
Acyclovir	5	5	5	5	5	5	5	5	**5**
Omeprazole	160	160	160	160	160	160	160	160	**160**
Tracaganth	200	400	600	800	-	-	-	-	**400**
Carbopol	-	-	-	-	200	400	600	800	**400**
PPG	4	4	4	4	4	4	4	4	**4**
Triethanolamine	4	4	4	4	4	4	4	4	**4**
Water	**Qs**	**Qs**	**Qs**	**Qs**	**Qs**	**Qs**	**Qs**	**Qs**	**Qs**

Figure.1: Nanogel formulation of acyclovir and omeprazole

CHARACTERIZATION OF NANOGEL:

pH: Direct estimations were made utilizing a computerized pH meter (MK-IV SYSTRONICS). Thickness assurance Viscosities were resolved utilizing cone and plate viscometer (Computerized Rheometer model DV1, Brookfield) of the gels ready. A shaft (no. 7) was pivoted at 10 rpm.

Homogeneity test: The plans were tried for their homogeneity by visual appearance after the gels have been set in the holder. Likewise, a little amount of each gel is squeezed between the thumb and the pointer, and the consistency of the gel is seen regardless of whether homogeneous. [137].

Spreadability: Not entirely set in stone by applying weight to glass slides into which definition was set, and time in seconds expected to isolate the slides was noted. Spreadability of every plan was accounted for in a moment or two. Spreadability was then determined by utilizing the recipe:

$$S = M.L/T \quad (1)$$

Where, S = Spreadability, M = weight tide to upper slide, L = length of glass slide, and T = time taken to isolate the slide totally from one another.

Viscosity: The consistency of the details not entirely settled at 25°C by utilizing Brookfield viscometer with axle no. S-96 at 1 rpm and consistency was estimated in cps. The estimation of every detailing was finished in three-fold and normal qualities are determined.

Determination of Rate Yield: Nanogel of acyclovir and omeprazole were weighed after definitions. Rate yield was determined

$$\text{Rate yield} = \frac{\text{Useful load of nanosponges obtained}}{\text{theoretical weight(drug + polymers)}} x100$$

Drug Substance: Drug not entirely settled by ultra-centrifugation strategy. Nanogel was disintegrated in axis tube containing 2 ml of refined water. The arrangement was centrifuged at 12,000 rpm for 10 minutes. It was sifted and supernatant arrangement was investigated utilizing UV noticeable spectrophotometer at 251 nm and 300nm.

Reasonable medication content

$$\text{Drug Content} = \frac{\text{Hypothetical medication content}}{x100}$$

In-vitro discharge study: The in vitro drug discharge from gel details was concentrated across cellulose films (Sigma Aldrich) utilizing Franz dispersion cells with compelling diffusional surface area of 3.14 cm2. The cellulose acetic acid derivation film (cellophane layer) having a pore size 33 mm was mounted between the contributor and receptor compartment of the dissemination cell. The collector compartment was loaded up with 15 ml of phosphate support pH 7.4 to guarantee sink condition. The contributor compartment of the cell was loaded up with 1 g vehicle containing the test drug. 0.5 ml test was removed at time periods hour for a time of 24 hours, and each time equivalent volume was supplanted with sans drug receptor liquid. All examples were examined by UV spectrophotometer at 200 nm - 400 nm. The analysis was completed in three-fold, and the mean aggregate rate sets free from three bunches were determined.

EVALUATION OF IMPROVED NANOGEL:

Particle size and Polydispersity list (PDI): The typical molecule size and PDI of improved Nanogel was resolved utilizing dynamic light dispersing utilizing Malvern Zetasizer (Nano ZS90, Malvern instruments) at 25°C. The examples were kept in polystyrene cuvette and the readings were estimated at a decent point.

Zeta potential: The zeta capability of advanced Nanogel was estimated utilizing Malvern Zetasizer (Nano ZS90, Malvern instruments) at 25°C. The examples were estimated by zeta dunk cell kept in polystyrene cuvette.

TEM (transmission electron magnifying lens): Transmission electron microscopy (TEM) is a microscopy procedure wherein a light emission is communicated through an example to shape a picture. The example is most frequently a ultrathin segment under 100 nm thick or a suspension on a framework.

In Vitro Medication Delivery Energy

The medication discharge energy of advanced detailing (still up in the air by plotting the accompanying dynamic models, utilizing the information gathered from in vitro discharge studies (zero request, first request and Higuchi conditions). The component of medication not entirely set in stone by utilizing Korsmeyer-Peppas conditions.

Zero-Request Energy:

This energy depicts focus autonomous medication discharge from the definitions.

First request energy:

First request diagram is plotted by log total level of medication remaining versus time. This energy depicts fixation subordinate medication discharge from the details.

$$\mathbf{Log\ C = Log\ Co + Kt/2.303}$$

Where C0 is the underlying convergence of medication, k is the primary request steady, and t is the time.

Higuchi's Model: Higuchi's model as total level of medication delivered versus square base of time.

$$\mathbf{Q = Kt1/2}$$

Where K is the steady mirroring the plan factors of the framework and t is the time in hours. This model depicts the arrival of medication based on Fickian dispersion as a square foundation of time subordinate interaction from swellable lattice.

Korsmeyer-Peppas Conditions: The system of medication discharge, the first 60% of medication discharge were plotted in Korsmeyer et al's condition log aggregate level of medication delivered versus log time, and the type n was determined through the slant of the straight line,

$$\mathbf{Mt/M\infty = Ktn}$$

Where Mt/M∞ is the fragmentary solute discharge, t is the delivery time, K is a motor steady quality of the medication/polymer framework, and n is an example that describes the instrument of arrival of tracers. This sort of medication discharge is constrained by blend of polymer enlarging, disintegration and dissemination through hydrated network. The component of dissemination is distinguished from the upsides of 'n'.

Comparison Medication Delivery Information With Planned Nanogel And Advertised detailing. The in vitro discharge study was performed with examination of advanced detailing and advertised definition.

RESULTS AND DISCUSSION

PREFORMULATION STUDIES

Physical Characteristics:

Acyclovir And Omeprazole was checked for its tone, scent and surface. Acyclovir And Omeprazole is White hued powder apparently, unscented and undefined in nature.

Melting Point:

Softening mark of still up in the air by narrow cylinder technique and it was viewed as 2560C separately, which affirms the immaculateness of the medication.

Softening mark of still up in the air by narrow cylinder technique and it was viewed as 1560C separately, which affirms the immaculateness of the medication.

Solubility examinations:

The dissolvability of Acyclovir and omeprazole in dissimilar solvents like water, methanol, ethanol and pH 7.4 was finished. The outcomes shows that the Acyclovir drug is sparingly dissolvable in water , methanol and its exceptionally solvent in cushion PH 7.4 and ethanol . Omeprazole is sparingly solvent in ethanol and its exceptionally dissolvable in water, methanol and cradle pH 7.4.

Table.2: Solubility Studies Data Of Acyclovir and Omeprazole nanogel

S.No	Acyclovir with solvent	Inference	Omeprazole with solvent	Inference
1	Water	Sparingly soluble	Water	Soluble
2	Methanol	Sparingly soluble	Methanol	Soluble
3	buffer pH 7.4	Soluble	buffer pH 7.4	Soluble
4	Ethanol	Soluble	Ethanol	Sparingly soluble

Determination of λ max:

The highest concentration (µg/ml) from the dilution was chosen for determination of λ max. The λ max of acyclovir was found to be 251 nm.



Figure.2: λ max of acyclovir

Determination of Omeprazole λ max:

The highest concentration (µg/ml) from the dilution was chosen for determination of λ max. The λ max of omeprazole was found to be 302 nm.



Figure.3: λ max of Omeprazole

Determination of Standard graph:

Standard diagram was developed with convergence of 2 to 10 µg/ml. The absorbance was resolved relating to their fixation were displayed in table 6 . Connection coefficient was viewed as r2=0.9918 which shows standard diagram was straight.

Table.3: Calibration data of Acyclovir

S.No	Calibration data	Absorbance at 251 nm
1	2	0.050
2	4	0.118
3	6	0.202
4	8	0.247
5	10	0.307



Figure.4: Standard graph curve of acyclovir

Determination of Standard graph:

Standard diagram was developed with convergence of 2 to 10 µg/ml. The absorbance was resolved relating to their fixation were displayed in table 7 . Connection coefficient was viewed as r2=0.9872 which shows standard diagram was straight.

Table.4: Calibration data of Omeprazole

S.No	Calibration data (µg/ml)	Absorbance at 305 nm
1	2	0.116
2	4	0.312
3	6	0.452
4	8	0.647
5	10	0.870



Figure.5: Standard graph of Omeprazole

Excipient Compatibility Studies:

FT IR Study:

Acyclovir:



Figure.6: FT-IR of Acyclovir

Table.5:FT- IR data of Acyclovir

Sl. No.	Wave number cm^{-1}	Assignment
1	3435.27	NH stretching
2	3175.78	OH stretching
3	2680.11	CH stretching
4	1213.51	C – O stretching
5	1701.11	C=O stretching
6	1628.54	C=N stretching

Omeprazole:



Figure.7: FT-IR of Omeprazole

Table.6:FT- IR data of Omeprazole

Sl. No.	Wave number cm^{-1}	Assignment
1	1410.65	S=O stretching
2	1774.24	NH bending
3	1266.89	C – O stretching
4	2945.42	C – H stretching

Carbapol 940 :



Figure.8 FTIR of Carbopol 940

Table.7 FT- IR data of Carbapol-940

Sl. No.	Wave number cm^{-1}	Assignment
1	3324.56	OH stretching
2	1700.59	C=O stretching
3	2940.23	CH stretching

Tri-ethanolamine:



Figure.9: FT-IR of Tri-ethanolamine

Table.8: FT- IR data of Tri-ethanolamine

Sl. No.	Wave number cm^{-1}	Assignment
1	3308.32	OH stretching
2	1405.33	C – N stretching
3	2945.60	CH stretching

Acyclovir Nanogel:



Figure.10: FT-IR of Acyclovir Nanogel

Table-12 :FT- IR data of Acyclovir Nanogel

Sl. No.	Wave number cm^{-1}	Assignment
1	3278.18	OH stretching
2	1637.30	C=N stretching
3	1410.26	C – O stretching

Acyclovir + Omeprazole Nanogel :



Figure.11: FT-IR of Acyclovir and Omeprazole Nanogel.

Table.9 FT-IR of Acyclovir And Omeprazole Nanogel

Sl. No.	Wave number cm^{-1}	Assignment
1	3317.30	OH stretching
2	1636.52	C=N stretching
3	1043.79	C – O stretching

Compatibility Study:

The FTIR of the above compounds are read up for its similarity. The Infrared Spectroscopy is utilized to concentrate on the utilitarian gathering present. The Acyclovir Programming interface contain practical gatherings NH, Goodness, CH, C - O, C=O and C=N extending at 3435.27 cm-1, 3175.78 cm-1, 2680.11 cm-1, 1213.51 cm-1, 1701.11 cm-1 and 1628.54 cm-1 pinnacles individually. The tops at 3278.18 cm-1, 1637.30 cm-1 and 1410.26 cm-1 shows utilitarian gatherings Gracious, C=N and C - O extending separately for Acyclovir GEL. The Omeprazole Programming interface contain S=O, NH, C-O and CN extending utilitarian gathering at 1410.65 cm-1, 1774.24 cm-1, 1266.89 cm-1 and 2945.42 cm-1 pinnacles individually. The retention top at 3324.56 cm-1, 1700.59 cm-1 and 2940.23 cm-1 of Carbopol 940 shows practical gatherings Gracious, C=O and CH extending separately. The Tri ethanolamine shows utilitarian gathering Gracious, C - N and CH extending at 3308.32 cm-1, 1405.33 cm-1 and 2945.60 cm-1 pinnacles separately. The mind boggling compound Acyclovir + Omeprazole GEL shows utilitarian gathering Goodness, C=N and C - O extending at 3317.30 cm-1, 1636.52 cm-1 and 1043.79 cm-1 separately. The perplexing shows slight deviation in tops yet are viable with the joined mixtures, which can deliver best combinational definition.

FORMULATION OF NANOGEL:

Table.10 Trial batches for formulation of Acyclovir and Omeprazole

Drug	Formulation code	Observed
Acyclovir and Omeprazole nanogel	**F1**	Light yellow
	F2	Solid in nature
	F3	Brown
	F4	Liquid in nature
	F5	Pale yellow
	F6	Pale orange
	F7	Semiliquid
	F8	Hard gel
	F9	transparent gel

CHARACTERISATION OF ACYCLOVIR AND OMEPRAZOLE NANOGEL:

Determination of pH

The pH of various detailing from F1 to F9 were displayed in Table. The pH shifts starting with one plan then onto the next as indicated by their polymer proportions with drug.

Homogeneity

All the gel details (F1-F9) showed great homogeneity with nonappearance of irregularities. Gels were viewed as straightforward and were liberated from presence of particles, consistency of gel, totals, unfamiliar matter and stage partition. Results are displayed.

Spreadability

Spreadability width for various definitions F1-F9 showed great spreadability for example gel is effectively spreadable. The outcomes are displayed in Table.

Viscosity

Every one of the details of Nanogel were exposed to Brookfield viscometer used to gauge the consistency (in cps) by dropping a cone joined to a holding pole from distance of 10 cm so that, it ought to fall on focus of the glass cup loaded up with Nanogel.

Table.11 Evaluation of formulated batches of Nanogel.

Formulation code	pH	Homogeneity	Spreadibility	Viscosity
F1	6.1	Homogenous	2.5	3459
F2	6.3	Homogenous	3.5	3356
F3	6.2	Homogenous	2.9	3268
F4	6.5	Homogenous	3.4	3498
F5	6.2	Homogenous	2.6	3295
F6	6.3	Homogenous	2.9	3501
F7	5.9	Homogenous	3.2	3340
F8	6.4	Homogenous	2.8	3351
F9	6.9	Homogenous	3.5	3528

Percentage yield analysis

The rate yield was least for detailing F2 (32%) and greatest for plan F9 (96.02%).From the outcomes we can presume that as the F9 has the most noteworthy rate yield . The rate yield of all plans is portrayed.



Figure.12: Percentage yield of Acyclovir and Omeprazole Nanogel

Drug content



Figure.13:Drug content of Acyclovir And Omeprazole Nanogel

The Medication content was viewed as most noteworthy for F9 detailing which is 92.65% and the least capture of medication was found for F2 definition .The arranged nanogel have high medication entanglement effectiveness and were found .

IN VITRO MEDICATION DELIVERY STUDIES

In vitro drug discharge investigation of the pre-arranged Acyclovir and Omeprazole Nanogel was done utilizing cellophane memberane by frantz dissemination cell. Measure of medication delivered in various time stretches were noticed.

Table 12:In vitro drug release profile of Acyclovir and Omeprazole Nanogel (F1-F3)

S.NO	TIME (h)	Cumulative percentage drug release (%)					
		F1		F2		F3	
		A	O	A	O	A	O
1	0	0	0	0	0	0	0
2	1	3.4	0.5	1.2	1.1	1.5	1.5
3	2	12.5	9.5	8.8	7.2	10.6	8.8
4	4	25.2	20.8	24.5	15.4	18.7	17.3
5	6	43.8	35.1	40.5	27.9	29.3	23.9
6	8	53.6	50.5	50.9	43.5	35.6	39.6
7	12	60.4	55.7	55.3	51.4	42.1	46.4
8	16	65.5	60.8	60.4	69.6	56.6	52.5
9	20	79.9	70.0	62.9	72.3	65.2	65.7
10	24	80.1	75.9	70.4	75.7	72.7	69.1



Figure.14:In vitro drug release profile of Acyclovir and Omeprazole Nanogel (F1-F3)

Table 13: In vitro drug release profile of Acyclovir and Omeprazole Nanogel (F4-F6)

S.NO	TIME (h)	Cumulative percentage drug release (%)					
		F4		F5		F6	
		A	O	A	O	A	O
1	0	0	0	0	0	0	0
2	1	2.2	1.5	1.5	3.8	8.1	5.2
3	2	8.6	12.4	11.1	15.5	17.6	12.2
4	4	20.8	24.1	23.3	28.9	30.2	23.8
5	6	33.5	33.8	32.9	45.2	38.8	31.3
6	8	46.5	48.9	41.5	51.1	41.5	43.8
7	12	55.2	56.1	52.7	65.8	48.2	51.1
8	16	61.9	66.6	61.2	69.7	51.8	63.8
9	20	68.8	73.4	73.8	71.3	68.3	68.2
10	24	71.5	75.2	75.4	78.8	75.4	72.8



Figure.15: In vitro drug release profile of Acyclovir and Omeprazole Nanogel (F4-F6).

Table 14: In vitro drug release profile of Acyclovir and Omeprazole Nanogel (F7-F9)

S.NO	TIME (h)	Cumulative percentage drug release (%)					
		F7		F8		F9	
		A	O	A	O	A	O
1	0	0	0	0	0	0	0
2	1	2.4	4.7	3.7	1.4	15.2	8.8
3	2	10.2	12.5	11.5	9.5	23.5	17.6
4	4	26.5	28.1	27.6	25.4	39.2	35.2
5	6	45.3	47.8	46.4	44.6	48.8	45.5
6	8	55.8	57.4	56.1	54.7	61.5	58.2
7	12	60.5	62.7	61.8	59.3	73.1	72.6
8	16	66.5	68.2	67.1	65.5	81.6	83.2
9	20	79.9	81.9	80.4	78.8	92.4	93.5
10	24	80.2	82.2	81.9	79.5	98.1	97.9



Figure.16:In vitro drug release profile of Acyclovir and Omeprazole Nanogel(F7-F9)

From the in vitro discharge information it was found that details F9 showed the best arrival of close to 100% and 97.5% separately toward the finish of 24 hrs among every one of the nine definitions of Acyclovir and Omeprazole Nanogel.

OPTIMIZATION OF ACYCLOVIR AND OMEPRAZOLE NANOGEL BY CHARACTERISATION:

Table 15: Optimization of Acyclovir And Omeprazole Nanogel By Characterization

S.NO	METHODS	OBSERVED	RESULT
1	pH	6.9	F9
2	Homogeneity	Homogenous	F9
3	Spreadability	3.5	F9
4	Viscosity	3528	F9
5	Percentage yield	96.02%	F9
6	Drug content	92.65%	F9
7	In-vitro dissolution study	99 (A)and 97.2(O)	F9

EVALUATION OF IMPROVED FIGURED OUT F9:

Particle size and Zeta Potential:

The molecule size is one of the main boundary for the portrayal of nanogel. The typical molecule sizes of the pre-arranged F9 nanogel estimated utilizing Malvern zeta sizer.

Molecule size examination showed that the typical molecule size of Acyclovir and omeprazole nanogel figured out utilizing (F9) was viewed as 678.4 nm with polydispersity record (PDI) esteem 0.842 and with catch 0.857. The zeta size dispersion of - Acyclovir and omeprazole nanogel is portrayed in Figure.

Table 16: Particle size and Zeta potential of formulation F9

S.No	FORMULATION CODE	PARTICLE SIZE	PDI	ZETA POTENTIAL
1.	F9	678.4	0.842	-43.7



Figure.17: Particle size and PDI of the formulation F9

Determination of Zeta Potential

Zeta Potential was resolved utilizing Malvern zeta-sizer instrument. Zeta potential investigation is completed to track down the surface charge of the particles to know its soundness during capacity. The size of zeta potential is prescient of the colloidal steadiness. Nanoparticles with zeta potential worth more noteworthy than +25 mV or not exactly - 25 mV regularly have high levels of steadiness. In the event that every one of the particles in suspension have an enormous negative or positive zeta potential then they will quite often repulse one another

and there will be no propensity for the particles to meet up. Be that as it may, in the event that the particles have low zeta expected values, there will be no power to forestall the particles meeting up and flocculating. For Acyclovir and omeprazole nanogel utilizing zeta potential was viewed as - 43.7 mV with top area of 100 percent power. These qualities demonstrate that the formed Acyclovir and omeprazole nanogel (F9) are steady. Zeta likely conveyance of Acyclovir and omeprazole nanogel arranged utilizing ethyl cellulose is portrayed in the Figure.



Figure.18: Zeta Potential of formulation F9

TEM (transmission electron microscope):

Transmission electron microscopy (TEM) is a microscopy method wherein a light emission is communicated through an example to frame a picture. The example is most frequently a ultrathin segment under 100 nm thick or a suspension on a matrix.



Figure.19: TEM image

IN-VITRO DRUG RELEASE KINETICS

The information got from the in vitro discharge study be situated utilized to squeeze into motor models. This was finished to figure out the component of medication discharge from Acyclovir and omeprazole nanogel F9. To decide the delivery model, the in vitro discharge information were examined by zero request energy. The inclination of a specific instrument depended on the coefficient of assurance (r2) for the boundaries contemplated, where the most elevated coefficient of assurance is liked for the choice of the request for discharge. The motor boundaries of Acyclovir and omeprazole nanogel F9. Since the r2 esteem is higher for zero request , it is chosen as the best fitted model. This was affirmed by plotting rate total medication delivery and square base of time and r2 esteem ranges somewhere in the range of 0.928 and 0.921. Be that as it may, in numerous trial circumstances, the component of medication dispersion digresses from the Fickian condition and follows a non- Fickian (bizarre) conduct. In these cases, the Korsemeyer-Peppas model was utilized to break down the delivery energy. It is seen that plan F9 adhered to Fick's law of dissemination and rest showed an irregular way of behaving.

ACYCLOVIR **OMEORAZOLE**



Figure.20 Graph of zero order kinetics



Figure.21: Graph of first order kinetics



Figure.22: Graph of Higuchi's

Figure.23:Graph of peppa's

Comparison of Acyclovir (ACIVIR) Marketed Formulation and Acyclovir And Omeprazole Nanogel:

Table 17: Acyclovir (ACIVIR) marketed formulation (MF) and acyclovir and omeprazole nanogel (F9)

Time(hrs)	*In-vitro* release percentage (%) for M F	*In vitro* release of nanogel (F9)
00	0	0
1	10	15
2	22	23
4	55	39
6	73	58
8	91	68
12	-	73
16	-	79
20	-	92
24	-	99



Figure.24: Comparision of Marketed Formulation (MF) and F9 Formulation

According to marketed formulation (MF) and F9 formulation have sustained release for 24 hrs.

SUMMARY

The λmax Acyclovir and Omeprazole were affirmed by UV spectrometer at range 251 nm and 305 nm. Standard not set in stone by different centralization of Acyclovir and Omeprazole. The current review showed that Acyclovir and Omeprazole nanogel were effectively evolved by dissolvable dispersion technique . pH was resolved different definition F1-F9 in that F9 have appropriate for gel readiness. Drug not set in stone by UV-spectroscopic strategy. The arranged nanogel was dark, with next to no irregularities, molecule and totals. Thus, every one of the definitions are homogenous. Spreadability measurement concentrate on F9 shown the nanogel is having great Spreadability. Nanogel details shown consistency territory from 3268-3528 cps. It presumed that they are steady in nature. In-vitro disintegration study was performed and showed that F9 have great disintegration rate. The molecule size, PDI and zeta potential to figure out the F9 plan. The molecule size, PDI and zeta potential was viewed as in 687.4, 0.842 and - 43.7 separately. TEM picture was affirmed the state of circular and smooth surface of particles at range 650 nm. Contrasting F9 nanogel detailing and acyclovir advertised plan (MF) by in-vitro discharge study. As indicated by result formed Acyclovir and omeprazole nanogel is more operative than the promoted acyclovir balm. Thus from our review the acyclovir and omeprazole nanogel (F9) showed that support drug discharge than the showcased definition, so it is apparent that forming into nanogel results increment the counter - viral action.

CONCLUSION

It very well may be presumed that the trial concentrate on completed that the plan of a Nanogel containing hostile to viral medication and hostile to ulcer drug yields a detailing with circular and smooth surface, nano in size range. The arranged nanogel was hazy, with practically no protuberances, molecule and totals. In this way, every one of the definitions are homogenous. In light of the relative multitude of variables the nanogel drug conveyance framework F9 shows great medication content contrast with other. The molecule size of the nanogel definition is ideal and it is under 1000 nm. Thus, it presumed that the particles are in minuscule and nano in size range. All nanogel definitions shows pH in the scope of 6.1 to 6.9. Detailing F9 shows most noteworthy pH of 6.9. Since the pH scope of nanogel were 1 to 7 pH. In view of the Spreadability breadth concentrate on it shown

the nanogel is having great Spreadability. Nanogel definitions shown consistency territory from 3268-3528 cps. It presumed that they are steady in nature. Plan F9 shows most elevated level of medication discharge contrast with different details. In-vitro dissemination concentrates on show F9 definition shows controlled discharge example of medication from the plan. The detailing was viewed as steady in transient soundness studies. Here we have chosen F9 has an upgraded definition which shown great morphological elements, drug content productivity and controlled drug discharge. Thus the F9 definition is effective than the advertised detailing of acyclovir balm (ACIVIR).

REFERENCES:

1. Asbill CS, Michniak BB. Percutaneous penetration enhancers: local versus transdermal activity. Pharm Sci Technol Today 2000;3:36–41.
2. Balaji P, Thirumal M, Gowri R, Divya V, Ramaswamy V. Design and evaluation of matrix type of transdermal patches of methotrexate. Int J Pharm Chem Biol Sci 2012;2:464–71.
3. Das PS, Saha P. Design and characterisation of transdermal patches of Phenformin hydrochloride. Int J Curr Pharm Res 2017;9:90–3.
4. Shivalingam M, Balasubramanian A, Ramalingam K. Non-invasive medicated dermal patch–a review. Int J Pharm Res 2020;12:3018–27.
5. Shivalingam MR, Balasubramanian A, Ramalingam K. Design and evaluation of medicated dermal patches of proton pump inhibitor-esomeprazole. Int J Pharm Res 2020;12:3038–43.
6. Funke AP, Schiller R, Motzkus HW, Gunther C, Muller RH, Lipp R. Transdermal delivery of highly lipophilic drugs: *in vitro* fluxes of antiestrogens, permeation enhancers, and solvents from liquid formulations. Pharm Res 2002;19:661–8.
7. Guy RH. Current status and future prospects of transdermal drug delivery. Pharm Res 1996;13:1765–9.
8. Luciani F., Spada M., De Milito A., Molinari A., Rivoltini L., Montinaro A., et al. (2004). Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J. Natl. Cancer Inst. 96 1702–1713. 10.1093/jnci/djh305
9. Ikemura K., Hiramatsu S., Okuda M. (2017). Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front. Pharmacol. 8:911. 10.3389/fphar.2017.00911.
10. Piret J., Boivin G. (2016). Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr. Opin. Infect. Dis. 29 654–662. 10.1097/qco.0000000000000288
11. Chen F., Xu H., Liu J., Cui Y., Luo X., Zhou Y., et al. (2017). Efficacy and safety of nucleoside antiviral drugs for treatment of recurrent herpes labialis: a systematic review and meta-analysis. J. Oral. Pathol. Med. 46 561–568. 10.1111/jop.12534
12. Zarrouk K., Piret J., Boivin G. (2017). Herpesvirus DNA polymerases: structures, functions and inhibitors. Virus Res. 234 177–192. 10.1016/j.virusres.2017.01.019
13. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K. (1972). Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177 705–706. 10.1126/science.177.4050.705
14. Koh C., Liang T. J. (2014). What is the future of ribavirin therapy for hepatitis C? Antiviral Res. 104 34–39. 10.1016/j.antiviral.2014.01.005